Efficacy of Darbepoetin Alfa in Alleviating Fatigue and the Effect of Fatigue on Quality of Life in Anemic Patients with Lymphoproliferative Malignancies

Journal of Pain and Symptom Management

Volumn 31, Issue 4, 2006, Pages 317-325

  Littlewood, Timothy J ^a   Kallich, Joel D ^a   San Miguel, Jesus ^a   Hendricks, Lisa ^a   Hedenus, Michael ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

anemia; darbepoetin alfa; fatigue; lymphoproliferative malignancies; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; INFORMATION PROCESSING; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

AGED; ANEMIA; ERYTHROPOIETIN; FATIGUE; FEMALE; HEALTH STATUS; HEMOGLOBINS; HUMANS; LEUKEMIA, LYMPHOCYTIC; LYMPHOMA; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33646487928     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2005.08.013     Document Type: Article

References (34)

1. Dicato M. Anemia in cancer: some pathophysiological aspects. Oncologist 8 Suppl 1 (2003) 19-21
2. Mercadante S., Gebbia V., Marrazzo A., and Filosto S. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 26 (2000) 303-311
3. Glaspy J.A., Jadeja J.S., Justice G., et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 97 (2003) 1312-1320
4. Cabanillas F., Burke J.S., Smith T.L., et al. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Arch Intern Med 138 (1978) 413-418
5. Coiffier B. The impact and management of anemia in haematological malignancies. Med Oncol 17 Suppl 1 (2000) S2-S10
6. Leonard J., Quinto C., Kozitza M., et al. Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 83 (1994) 1499-1506
7. Straus D.J., Testa M., Riggs S.A., et al. Early treatment with epoetin alfa improves anemia, quality of life (QOL), and productivity in patients (pts) with hematologic malignancies and mild anemia during chemotherapy (CT). [Abstract 1811]. Blood 102 (2003) 497a
8. Miller C.B., Jones R.J., Piantadosi S., et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322 (1990) 1689-1692
9. Evans W.J. Physical function in men and women with cancer. Effects of anemia and conditioning. Oncology (Williston Park) 16 (2002) 109-115
10. Richardson A. Fatigue in cancer patients: a review of the literature. Eur J Cancer Care (Engl) 4 (1995) 20-32
11. Cella D., Peterman A., Passik S., Jacobsen P., and Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 12 (1998) 369-377
12. Littlewood T.J. Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy. Front Radiat Ther Oncol 37 (2002) 34-37
13. Tchekmedyian N.S., Kallich J., McDermott A., et al. The relationship between psychologic distress and cancer-related fatigue. Cancer 98 (2003) 198-203
14. Vansteenkiste J., Pirker R., Massuti B., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
15. Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer 29A (2003) S2-S8
16. Case Jr. D.C., Bukowski R.M., Carey R.W., et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85 (1993) 801-806
17. Glaspy J.A., Jadeja J.S., Justice G., et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anemia associated with cancer chemotherapy. Br J Cancer 87 (2002) 268-276
18. ® practice guidelines in oncology-Version 1. 2004.
19. Barlogie B., and Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 11 (1993) 88-94
20. Dammacco F., Castoldi G., and Rodjer S. Efficacy of epoetin alfa in the treatment of anemia of multiple myeloma. Br J Haematol 113 (2001) 172-179
21. Garton J.P., Gertz M.A., Witzig T.E., et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155 (1995) 2069-2074
22. Ludwig H., Fritz E., Kotzmann H., et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322 (1990) 1693-1699
23. Mittelman M., Zeidman A., Fradin Z., et al. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 98 (1997) 204-210
24. Boogaerts M., Coiffier B., and Kainz C. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88 (2003) 988-995
25. Osterborg A., Brandberg Y., Molostova V., et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20 (2002) 2486-2494
26. Hedenus M., Adriansson M., San Miguel J., et al. Efficacy and safety of darbepoetin alfa in anemic patients wth lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122 (2003) 394-403
27. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (1997) 13-19
28. Yellen S.B., Cella D.F., Webster K., Blendowski C., and Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13 (1997) 63-74
29. Derogatis L.R. Brief Symptom Inventory administration, scoring and procedures manual (1993), NCS Pearson, Inc., Minneapolis, MN
30. Cella D., Elton D., Lai J.S., Peterman A.H., and Merkel D.E. Combining anchor and distribution based methods to derive clinically meaningful differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24 (2002) 547-561
31. Cella D., Hahn E.A., and Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11 (2002) 207-221
32. Cella D., Lai J.S., Chang C.H., Peterman A., and Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94 (2002) 528-538
33. Crawford J., Cella D., Cleeland C.S., et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95 (2002) 888-895
34. Cella D., Zagari M., Vandoros C., et al. Epoetin alfa treatment results in clinically significant improvements when referenced to the general population. J Clin Oncol 21 (2003) 366-373